BioPharmSignal logoBioPharmSignal

Biotech News

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Seres Therapeutics (MCRB)Seres TherapeuticsEarnings

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biotherapeutic programs in inflammatory and immune diseases Company pursuing partnerships and other

Open original release

Related news

MCRBSeres Therapeutics2026-03-12 11:00 EST

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

MCRBSeres Therapeutics2026-03-02 21:05 EST

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

View all latest news

Seres Therapeutics

Seres Therapeutics is a microbiome company that has worked to translate microbiome science into therapies for gastrointestinal and immune-related disease. Its journey has been shaped by high expectations and repeated resets.

Recent company news

MCRBSeres Therapeutics2026-07-08 11:00 EST

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

MCRBSeres Therapeutics2026-06-25 11:00 EST

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

MCRBSeres Therapeutics2026-06-05 11:00 EST

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

MCRBSeres Therapeutics2026-05-12 11:00 EST

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

MCRBSeres Therapeutics2026-05-05 11:00 EST

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Stock data

Close
4.85 USD
Market cap
70.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States